Skin / hair / cosmetic peptides

Peptides studied mostly in topical/cosmetic contexts for skin and collagen biology.

Tier fingerprint · 4 compounds

S is approval-grade evidence; F is documented harm or near-zero human data. Each bar is how many peptides on this page land in that tier — a fast read on how much of this category sits in approval-grade evidence versus thin or vendor-driven claims.

S
0
A
0
B
0
C
0
D
3
F
1

The category at a glance

Every compound here ranked S–F by its weighted evidence score — strongest human / approval-grade evidence at the top, thin or vendor-driven claims at the bottom. Tap any row for the evidence read. Popularity never raises a tier.

Receipts, not vendor theater. Every tier here is computed from published evidence and regulatory status — not vendor marketing or influencer claims. See how we score.

D
ghk-cu
Early human evidenceMedium overstatementResearch-use-only
45
/ 100

A copper-binding tripeptide with the most evidence in topical/cosmetic skin contexts (collagen, antioxidant and regenerative signalling). Systemic/injectable human evidence is limited; much of the support is in-vitro or small skin studies. Reasonable cosmetic rationale, thin systemic data.

Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by preclinical depth. Why not C: held back by human evidence, regulatory clarity.

Read the full ghk-cu profile →
D
argireline
Early human evidenceMedium overstatementResearch-use-only
39
/ 100

A topical cosmetic peptide (acetyl hexapeptide-3/8) modelled on SNAP-25, claimed to soften expression lines by interfering with neurotransmitter release. Evidence is small, short-term cosmetic studies (e.g. reduced periorbital wrinkle roughness vs placebo over 4 weeks); effects are modest and below pharmaceutical standards.

Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by its overall evidence profile. Why not C: held back by human evidence, preclinical depth, regulatory clarity.

Read the full argireline profile →
D
matrixyl
Early human evidenceMedium overstatementResearch-use-only
37
/ 100

A topical cosmetic signal peptide (palmitoyl pentapeptide / pal-KTTKS) intended to stimulate dermal matrix synthesis. Supporting data are small split-face cosmetic trials showing modest fine-line improvement with good tolerability — cosmetic and incremental, not clinically dramatic.

Tier read: early human evidence · medium overstatement risk · low search interest · Early human. Why not F: supported by its overall evidence profile. Why not C: held back by human evidence, preclinical depth, mechanism confidence, regulatory clarity.

Read the full matrixyl profile →
F
ptd-dbm
Weak human evidenceHigh overstatementResearch-use-only
12
/ 100

A cell-penetrating peptide that activates Wnt/β-catenin signalling (disrupting CXXC5–Dishevelled), with reported hair-regrowth effects in mouse models. Evidence is animal/lab only — no completed human efficacy trials. Investigational, not an approved hair-loss treatment.

Tier read: weak human evidence · high overstatement risk · low search interest · Anecdote. Why not D: held back by human evidence, preclinical depth, mechanism confidence, safety clarity, regulatory clarity, practical relevance.

Read the full ptd-dbm profile →

Skin, hair, and cosmetic peptides are mostly a topical story. The better-supported compounds here work in creams and serums on skin biology; the weakest claims are the systemic “anti-aging from a peptide” ones that the cosmetic evidence never established.

Too earlyMostly preclinical or early-stage; human support is thin.
ghk-cuD
Research-use-only
matrixylD
Research-use-only
argirelineD
Research-use-only
High cautionSpeculative, weak human data, or heavily overhyped.
ptd-dbmF
Research-use-only
Not proven for this goal
Systemic anti-aging from topical useGuaranteed hair regrowthReversing aging

What the evidence actually supports

Topical cosmetic peptides — GHK-Cu (a copper tripeptide), Matrixyl (a palmitoyl peptide), and Argireline (acetyl hexapeptide) — are studied for collagen/matrix support and softening expression lines, in cosmetic contexts. The effects are real but modest and local.

Where the hype outruns the data

“Reverses aging,” “guaranteed regrowth,” and systemic anti-aging from a topical are not what the evidence shows. Argireline is far weaker than the injectable it's compared to; hair-regrowth peptides like PTD-DBM are mostly animal-stage.

FAQ

Do skin peptides actually work?

Topically, the cosmetic evidence for collagen/skin support is reasonable but modest. Systemic anti-aging claims are not established.

Will peptides regrow hair?

Hair-regrowth peptide evidence is early and mostly preclinical; it isn't well established in controlled human studies.

Is this medical advice?

No — research reference only.

← All goalsFull tier board

Research reference only. Not medical advice, dosing, or a recommendation to use any compound. “Worth watching” ≠ proven or safe.

The all-in-one peptide app

Stop reading, start tracking.

PepCue logs your doses, runs the vial math, counts your vials, and keeps the whole protocol in one place. It replaces the spreadsheet, the calculator, and the sticky notes.

  • Dose logging
  • Reconstitution math
  • Smart reminders
  • Vial & cost tracking
iPhone · free to start